Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 03.17
    2008

    Disclosure of Shareholdings in Accordance with Stock Market Rules

  • 02.26
    2008

    Addex Pharmaceuticals 2007 Financial Results

  • 02.25
    2008

    Addex Achieves First Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.

  • 01.03
    2008

    Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia

  • 01.03
    2008

    Addex Announces ADX10059 Phase IIa Acute Anxiety Data

  • 12.03
    2007

    Addex and Merck & Co. Collaborate to Develop Drugs for Parkinson’s Disease

  • 11.29
    2007

    Addex Pharmaceuticals Confirms Extension of Major Shareholder Lock-up

  • 10.29
    2007

    Addex Presents ADX10059 GERD Data at Conference

  • 10.01
    2007

    ADX10061 Smoking Cessation Data

  • 08.17
    2007

    Addex Pharmaceuticals appoints Head of ADME/PK

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics